Sabra Health Care REIT, Inc. Forecast, price target & analysts
Sabra Health Care REIT, Inc. Target price 2025 - Analyst rating & recommendation
Sabra Health Care REIT, Inc. Classifications & Recommendation:
Sabra Health Care REIT, Inc. Price Target
| Target Price | $19.60 |
| Price | $16.45 |
| Potential |
19.15%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Sabra Health Care REIT, Inc. 2026 .
The average Sabra Health Care REIT, Inc. target price is $19.60.
This is
19.15%
register free of charge
$21.00
27.66%
register free of charge
$17.00
3.34%
register free of charge
|
|
| A rating was issued by 11 analysts: 6 Analysts recommend Sabra Health Care REIT, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sabra Health Care REIT, Inc. stock has an average upside potential 2026 of
19.15%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 706.45 | 728.66 |
| 7.72% | 3.14% | |
| EBITDA Margin | 63.63% | 62.36% |
| 0.20% | 2.00% | |
| Net Margin | 18.16% | 23.48% |
| 735.54% | 29.29% |
5 Analysts have issued a sales forecast Sabra Health Care REIT, Inc. 2025 . The average Sabra Health Care REIT, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Sabra Health Care REIT, Inc. EBITDA forecast 2025. The average Sabra Health Care REIT, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Sabra Health Care REIT, Inc. Analysts have issued a net profit forecast 2025. The average Sabra Health Care REIT, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.54 | 0.72 |
| 800.00% | 33.33% | |
| P/E | 22.85 | |
| EV/Sales | 8.63 |
3 Analysts have issued a Sabra Health Care REIT, Inc. forecast for earnings per share. The average Sabra Health Care REIT, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Sabra Health Care REIT, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sabra Health Care REIT, Inc....
Current Sabra Health Care REIT, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citizens Capital Markets | Locked ➜ Locked | Locked | Feb 21 2025 |
| Truist Securities | Locked ➜ Locked | Locked | Jan 17 2025 |
| JMP Securities | Locked ➜ Locked | Locked | Jan 07 2025 |
| Mizuho | Locked ➜ Locked | Locked | Dec 05 2024 |
| Scotiabank | Locked ➜ Locked | Locked | Oct 11 2024 |
| Citigroup | Locked ➜ Locked | Locked | Sep 13 2024 |
| Truist Securities | Locked ➜ Locked | Locked | Sep 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citizens Capital Markets: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Jan 17 2025 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Jan 07 2025 |
|
Locked
Mizuho: Locked ➜ Locked
|
Dec 05 2024 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Oct 11 2024 |
|
Locked
Citigroup: Locked ➜ Locked
|
Sep 13 2024 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Sep 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
